

# CHANGE LOG: RELEASE NOTES REDCap ABMTRR Cell Therapy Project

## Version 2.22.6 (Released May 2021)

Changes in this version:

### FORM: Patient Information 2.22.6

### **REMOVAL OF QUESTION(S)**

Removal of all upload file fields

### FORM: Disease Classification 2.22.6

### **REMOVAL OF QUESTION(S)**

- Removal of all upload file fields
- LYMPHOMA removed the known / unknown field for Deauville score

### **CHANGE TO QUESTION(S)**

ALL classification - Update of choices from the dropdown list

### FORM: ALL Preinfusion 2.22.6

### CHANGE TO QUESTION(S)

 Section 3. DISEASE TREATMENT PRIOR TO PREPARATIVE REGIMEN / INFUSION. Addition of *Bridging to Cell Infusion* for Therapy type

### FORM: Lymphoma Pre Infusion 2.22.6

### **REMOVAL OF QUESTION(S)**


- Section 7. DISEASE TREATMENT PRIOR TO INFUSION. Removal of *Known / Unknown* questions for each therapy line (1-7) for therapy: *Systemic therapy / Intrathecal therapy / Intraocular therapy / Radiation therapy / Surgery*.
- Removal of all upload file fields

### **CHANGE TO QUESTION(S)**

- Section 7. DISEASE TREATMENT PRIOR TO INFUSION. Specify regimen: Update of choices from the dropdown list
- Section 7. DISEASE TREATMENT PRIOR TO INFUSION. *Other systemic drugs:* Update of choices from list

### ADDITIONAL QUESTION(S)

Section 7. DISEASE TREATMENT PRIOR TO INFUSION. Addition of question for each treatment:



🥒 🖈 🐚 😤 🗶	Variable: lympre_tx1_bridge	Branching logic: [lympre_tx1_yn] = '1'	
Line of therapy wa	as bridging to cell infus	ion? O Yes O No reset	

### FORM: CELL THERAPY Preinfusion 2.22.6

#### **ADDITIONAL QUESTION(S)**

- Section 1. PATIENT IDENTIFICATION. Addition of Date of first referral.
- Section 5. PRODUCT IDENTIFCATION. Addition of *Final product read for shipping / Final product shipped*.
- Section 5. PRODUCT IDENTIFCATION. Additional question: *Actual setting of infusion INPATIENT / OUTPATIENT*.
- Section 9. LYMPHODEPLETING THERAPY. Removal of therapy table, each therapy is now listed and shows sub-questions when YES is selected for each therapy. Additional questions include: Was there a XXXX dose reduction YES | NO, if yes, % XXXX dose reduction / Reason XXXX dose reduction.

9. LYMPHODEPLETING THERAPY	
Lymphodepleting therapy given	🕒 🖲 Yes 🔿 No reset
	given prior to infusion
Bendamustine	<sup>IE</sup> ● Yes ○ No
Bendamustine total dose	B Daily dose x number of days
Bendamustine units	
Was there a bendamustine dose reduction	<sup>I®</sup> ● Yes O No
% bendamustine dose reduction	₩
Reason bendamustine dose reduction	0 0
Bendamustine Date started	H D-M-Y

- Section 9. LYMPHODEPLETING THERAPY. Addition of Cytarabine to therapy list.
- Section 10. PATIENT ASSESSMENT. Addition of question: ECOG prior to cell therapy. ECOG Performace Status 0 4 (including reference table).
- Section 11. COMORBID CONDITIONS. Addition of question: Were there any co-existing diseases or organ impairment
  present according to the HCT comorbidity index (HCT-CI)? YES | NO (within 3 months prior to the infusion, unless noted as ANY history
  in the list of coexisting diseases). If yes, complete the Comorbidities.

### FORM: CELL THERAPY Infusion 2.22.6

#### CHANGE TO QUESTION(S)

 Section 3 – CELL DOSES. Text for reporting total number of cells now reads: Report total number of cells in the product given (not cell per kg)

#### ADDITIONAL QUESTION(S)



Section 2 – INFUSION. New calculated fields for follow up dates (based on date of infusion). Questions will only appear when Product was infused = YES.

Follow up Dates (based on date of infusion)	
30 day follow up date	B 30-10-2020 View equation
100 day follow up date	(H) 08-01-2021 View equation
6 month follow up date	(e) 30-03-2021 View equation
1 year follow up date	B 30-09-2021 View equation

### FORM: CELL THERAPY Follow Up 2.22.6

#### **REMOVAL OF QUESTION(S)**

- Section 5 PERIPHERAL BLOOD COUNT RECOVERY. Removal of question Initial recovery previously reported?
- Section 7 Current Haematology Values. Removal of unknown fields for each Haematology type.
- Section 15 MAXIMUM LAB VALUES SINCE LAST REPORT. Removal of Interferon gamma and interferon date questions

#### **CHANGE TO QUESTION(S)**

- Section 4. BEST RESPONSE TO CELLULAR THERAPY. Questions are hidden if Tisagenlecleucel or Axicabtagene ciloleucel are selected for *Name of Product*.
- Section 7 Current Haematology Values. Data value unit change for Neutrophils from % to x10^9/L. Current data values have been udpated to reflect the change.
- Section 11. TOXICITIES CYTOKINE RELEASE SYNDROME. CRS therapy removal of *No Therapy Given* option from the therapy list and corrected spelling for Tocilizumab.
- Section 12 TOXICITIES NEUROTOXICITY. *Treatment for neurotoxicity* add *Anakinra* to list of treatments.
- Section 12 TOXICITIES NEUROTOXICITY. Treatment for neurotoxicity removal of No Therapy Given option from the therapy list.
- Section 14. GRADE 3 OR 4 TOXICITIES (CTCAE v5.0). Developed grade 3 organ toxicity removal of text 'Answer for Kymriah product only'.
- Section 14. GRADE 3 OR 4 TOXICITIES (CTCAE v5.0). Developed Grade 4 organ toxicity removal of text 'Applies to all products'.
- Section 14. GRADE 3 OR 4 TOXICITIES (CTCAE v5.0). For Grade 3 and Grade 4 organ toxicity removal of 'specify organ', and replaced question: Specify toxicity with dropdown choices, dependent on organ involvement.



Developed grade 3 organ toxicity	<ul> <li>Yes</li> <li>No</li> <li>Unknown</li> <li>Fest</li> <li>Severe or medically significant but not immediately life- threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care Activities of Daily Living</li> </ul>
Organ involved	🔒 Cardiovascular/Cardiac 🗸
Specify toxicity	Capillary leak syndrome Cardiac arrhythmia Hypertension Left ventricular systolic dysfunction Wyocardial infarction Pericardial effusion Pericarditis Restrictive cardiomyopathy Thromboembolic event

- Section 12 TOXICITIES NEUROTOXICITY. Treatment for neurotoxicity removal of No Therapy Given option from the therapy list.
- Section 16. INFECTION. Replacement of organism text field with a dropdown list.

#### **ADDITIONAL QUESTION(S)**

Section 5 – PERIPHERAL BLOOD COUNT RECOVERY. Addition of questions: (ANC recovery)

5. PERIPHERAL BLOOD COUNT RECOVERY Complete this section for 30 day, 100 day, 6 month, 1 and 2	year follow up
Initial neutrophil recovery	<ul> <li>N/A, never below 0.5 x10^9/L ✓</li> <li>ANC&gt;=0.5x10^9/L</li> </ul>
Subsequent ANC decline following initial recovery	Hesic O No ANC < 0.5 for >=3days since last report
ANC decline date	H Today D-M-Y
Did ANC recover	Image: Here is a set of the s
ANC recovery date	H Today D-M-Y
Initial platelet recovery	N/A; never below 20 x10^9/L → Plt>=20x10^9/L, earliest recovery date is at least 7 days after last platelet transfusion

- Section 7 Current Haematology Values. Addition of a new question: Growth factors were given <= 7 days prior YES |NO
- Section 11. TOXICITIES CYTOKINE RELEASE SYNDROME. CRS Therapy given YES NO.
- Section 11. TOXICITIES CYTOKINE RELEASE SYNDROME. If Tocilizumab is selected as CRS Therapy given, Doses of tocilizumab is required 1 | 2 or more.
- Section 11. TOXICITIES CYTOKINE RELEASE SYNDROME. CRS Symptoms. If Vasopressor(s) given = Yes, additional questions apply:



Hypotension requiring therapy	🖗 🖲 Yes 🔿 No 🔿 Unknown 👳	eset
Date of onset	H Today D-M-Y	
Intravenous fluids given	<sup>®</sup> ○ Yes ○ No ○ Unknown ☞	eset
Vasopressor(s) given	🛞 🖲 Yes 🔿 No 🔿 Unknown 🥪	eset
Number of vasopressors used for therapy	₿	
Vasopressor(s) used	<ul> <li>□ Phenylephrine</li> <li>□ Norepinephrine</li> <li>□ Epinephrine</li> <li>□ Dopamine</li> <li>□ Vasopressin</li> <li>☑ Other</li> </ul>	
other vasopressor	₩ ₽	

Section 11. TOXICITIES – CYTOKINE RELEASE SYNDROME. CRS Symptoms. If Any features related to MAS/HLH = Yes, additional questions apply:

Any features related to MAS/HLH	S Yes O No     reset     Macrophage activation syndrome / haemophagocytic     lymphohistiocytosis
MAS/HLH date onset	H Today D-M-Y
Splenomegaly associated with MAS/HLH	<sup>®</sup> ○ Yes ○ No
MAS/HLH confirmed by BM Biopsy	<sup>®</sup> ○ Yes ○ No
Lowest fibrinogen level	H at time of MAS/HLH diagnosis
fibrinogen units	<sup>B</sup> ○ mg/dL ○ mg/L
Fibrinogen date of sample	H Today D-M-Y
Highest Triglyceride level	H at time of MAS/HLH diagnosis
triglyceride units	<sup>IB</sup> ○ mg/dL ○ mmol/L
Triglyceride date of sample	H Today D-M-Y

- Section 12 TOXICITIES NEUROTOXICITY. Treatment for neurotoxicity was given YES | NO
- Section 16. INFECTION. Addition of *other organism* field if other organism is selected from the dropdown list.

### FORM: Lymphoma Post Infusion 2.22.6

#### **ADDITIONAL QUESTION(S)**

 Section 5. DISEASE STATUS AT TIME OF EVALUATION (for this reporting period). Current disease status by PET (metabolic) criteria = Not Assessed new question: Reason not assessed (at 12 months).



5. DISEASE STATUS AT TIME OF EVALUATION (for this reporting	period)	
Current disease status by CT (radiographic) criteria	B Complete remission (CR)	~
Date assessed	H Today D-M-Y	
Current disease status by PET (metabolic) criteria	$\stackrel{\mathbb{B}}{\Rightarrow}$ Not assessed	~
Reason not assessed	H at 12 months	~

# FORM: New Malignancy 2.22.6

# **REMOVAL OF QUESTION(S)**

Removal of all upload file fields



# **<u>NEW FORM</u>**: Preinfusion Documentation 2.22.6

The new form will now contain all the attached documentation related to pre infusion.

Event Name: Cell Therapy			
AID (ABMTRR ID)		100001	
Date of infusion	e P	Documentation relates to this infusion date	
Assessments prior to infusion			
FISH at diagnosis	H P		1 Upload file
Karyotyping at diagnosis	H		1 Upload file
Pathology report at diagnosis	Đ		1 Upload file
FISH between diagnosis and last assessment	H		1 Upload file
		Relevant for AML and ALL	
Karyotyping between diagnosis and last assessment	) H	Relevant for AML and ALL	<b>⊥</b> <u>Upload file</u>
FISH at last assessment	H		1 Upload file
Karyotyping at last assessment	H		1 Upload file
MRD at last assessment	H		1 Upload file
		Lymphoma	
Lymphoma transformation prior to infusion			
Pathology report at lymphoma transformation	H		1 Upload file
Karyotyping at lymphoma transformation	) H		1. <u>Upload file</u>
FISH at lymphoma transformation	H		1 Upload file
Monoclonal gammopathy of renal significance documentation	ı		
MRGS pathology report	) P		1. Upload file
HLA reports			
HLA recipient	Ð		1. <u>Upload file</u>
HLA donor	H P		1 Upload file
HLA second donor	Đ		1 Upload file
HLA third donor	H		1. Upload file



# **NEW FORM:** Postinfusion Documentation 2.22.6

The new form will now contain all the attached documentation related to post infusion.

Event Name: Cell Therapy Follow Up	
AID (ABMTRR ID)	100001
Infusion date	•
* must provide value	Documentation relates to this infusion date
	○ 30 day
	O 100 day
Follow up period	⊖ 6 month
* must provide value	O 1 year O 2 year
	○ 2 year ○ >2year
	re
Best disease response post infusion	
FISH at best response	🕒 🥏 🎝 🎝 🕹 🕹
•	
Karyotyping at best response	H Linland 6
Pathology report at best response	🛞 🔔 Upload fi
ratiology report at best response	Lymphoma
	Lymphoma
Disease relapse or progression	
FISH at relapse/progression	(H) p L Upload fi
Karyotyping at relapse/progression	(H) p L Upload fi
	~ ·
Pathology at relapse/progression	🕒 🏦 Upload fi
	e.g. lymphoma biopsy report
Assessments at current follow up	
FISH at this follow up	
Karyotyping at this follow up	θ
Raryotyping at this follow up	
New malignancy	
New malignancy diagnosis	
new manghaney angliosis	
New malignancy donor/cell product derived	
New manghancy donor/cen product derived	
PTLD biopsy report	Θ
	⊖ <b>±</b> <u>Upload fi</u>
Cause of death	
Autonov konost	Θ
Autopsy report	⊖ <b>±</b> <u>Upload fi</u>
Other	
	•
other documentation	🦕 🗘 Upload fi